Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20188219 | 0.98 | APLNR (0.43) | APLNRKDM4EALDH1A1GAAMAPT | |
| SCHEMBL20168848 | 0.81 | APLNR (0.46) | APLNRKDM4E | |
| SCHEMBL20189145 | 0.78 | APLNR (0.67) | APLNRKDM4EALDH1A1GAAMAPT | |
| SCHEMBL18247184 | 0.78 | APLNR (0.43) | APLNRKDM4EALDH1A1GAAMAPT | |
| SCHEMBL19551005 | 0.78 | APLNR (0.47) | APLNRKDM4E | |
| SCHEMBL18246405 | 0.78 | APLNR (0.67) | APLNR | |
| SCHEMBL26097655 | 0.77 | APLNR (0.39) | APLNRKDM4E | |
| SCHEMBL12457564 | 0.70 | APLNR (0.37) | APLNRALDH1A1 | |
| SCHEMBL12457576 | 0.68 | DHFR (0.35) | APLNRKDM4EALDH1A1GAAMAPT | |
| SCHEMBL26023589 | 0.67 | APLNR (0.37) | APLNRKDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-3704122-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AP3M1, GPBAR1 | APLNR 5/4885KDM4E 4641/4885ALDH1A1 2156/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | APLNR 5/4885KDM4E 4641/4885ALDH1A1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.